Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

3(60.0%)

Phase 3

1(20.0%)

Phase 4

1(20.0%)

5Total

N/A(3)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT03670836Phase 4Completed

Comparison of Misoprostol Ripening Efficacy With Dilapan

Role: collaborator

NCT03665688Not ApplicableCompleted

Comparing Outpatient to Inpatient Cervical Ripening Using Dilapan-S®

Role: collaborator

NCT04739683Not ApplicableWithdrawn

Cervical Ripening With Foley Bulb Versus Dilapan-S at Home

Role: collaborator

NCT03001661Phase 3Completed

An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt

Role: collaborator

NCT02899689Not ApplicableCompleted

Induction of Labor in Women With Unfavorable Cervix: Dilapan Versus Foley Bulb

Role: collaborator

NCT02318212Completed

Dilapan-S / Dilasoft E-Registry in Induced Abortion

Role: lead

NCT02318173Completed

Dilapan-S/Dilasoft E-Registry in Induction of Labor

Role: lead

NCT02098382Completed

Dilapan-S Osmotic Dilator in Pre-induction of Labor

Role: lead

All 8 trials loaded